Kamada (NASDAQ: KMDA) is one of 50 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Kamada to similar companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, profitability and risk.
Valuation and Earnings
This table compares Kamada and its peers revenue, earnings per share (EPS) and valuation.
Kamada’s peers have higher revenue and earnings than Kamada. Kamada is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Kamada and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional and Insider Ownership
7.3% of Kamada shares are held by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
Kamada has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Kamada’s peers have a beta of 1.18, meaning that their average stock price is 18% more volatile than the S&P 500.
This is a summary of recent ratings for Kamada and its peers, as reported by MarketBeat.
||Strong Buy Ratings
Kamada currently has a consensus price target of $8.50, suggesting a potential upside of 91.01%. As a group, “Biopharmaceuticals” companies have a potential upside of 12.50%. Given Kamada’s stronger consensus rating and higher probable upside, equities analysts plainly believe Kamada is more favorable than its peers.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.